Current and emerging treatments for multiple myeloma

Journal of Managed Care Pharmacy

Volumn 14, Issue 7 SUPPL., 2008, Pages

  Schwartz, Rowena N ^a   Vozniak, Michael ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CORTICOSTEROID; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; HEAT SHOCK PROTEIN 90 INHIBITOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; M PROTEIN; MELPHALAN; PAMIDRONIC ACID; PERIFOSINE; PLACEBO; PREDNISONE; PROTEASOME INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALINOSPORAMIDE A; SULFAMETHOXAZOLE; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; THALIDOMIDE; TRIMETHOPRIM; UNINDEXED DRUG; WARFARIN;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BEDTIME DOSAGE; BLOOD TOXICITY; BONE DISEASE; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; BONE PAIN; BRADYCARDIA; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DIZZINESS; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; GASTROINTESTINAL DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HUMAN; HYPOTHYROIDISM; IMPOTENCE; INFECTION; INSOMNIA; KIDNEY DISEASE; LOW DRUG DOSE; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; NAUSEA; NEUROPATHIC PAIN; NEUTROPENIA; OSTEOPENIA; PERCUTANEOUS VERTEBROPLASTY; PERIPHERAL NEUROPATHY; PHYSICAL ACTIVITY; PROGNOSIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TERATOGENICITY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

EID: 54449086374     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2008.14.s7-a.12     Document Type: Review

References (43)

1. Fonseca R, San Miguel J. Prognostic factors and staging in multiple myeloma. Hematol Oncol Clin North Am. 2007;21:1115-40.
2. International Myeloma Foundation. What is nonsecretory myeloma? Available at: http://myeloma.org/main.jsp?source= link&source_link_id=284&type=article&tab_id= 3&menu_id=59&id=299. Accessed August 5, 2008.
3. The NCCN Multiple Myeloma Clinical Practice Guidelines in Oncology (Version 1.2008) ©2007 National Comprehensive Cancer Network, Inc. Available at: www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf. Accessed March 19, 2008.
4. Multiple Myeloma Research Foundation. Diagnosis and Staging. Available at: www.multiplemyeloma.org/about_myeloma/2.05.php. Accessed March 16, 2008.
5. Rajkumar SV. Thalidomide: tragic past and promising future. Mayo Clin Proc. 2004;79:899-903.
6. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004; 351:1860-73.
7. Tosi P, Zamagni E, Cellini C, et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol. 2004; 73:98-103.
8. United States Food and Drug Administration. Proposed changes to approved thalidomid package insert. Available at: http://fda.gov/cder/foi/label/ 2006/021430s000,020785s031bl.pdf. Accessed July 21, 2008.
9. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis, JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24:4507-14.
10. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825-31.
11. Cleveland Clinic. Available at: www.clevelandclinicmeded.com/medicalpubs/ diseasemanagement/cardiology/vtrhomboembolism/vthromboembolism.htm. Accessed June 5,2008.
12. Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma (letter). N Engl J Med. 2001; 344:1951.
13. Auwerda JJ, Sonneveld P, de Maat, et al. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica. 2007;92:279-80.
14. Zervas K, Dimopoulos MA, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli C, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol. 2004;15:134-38.
15. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962-72.
16. Merchionne F, Perosa F, Dammacco F. New therapies in multiple myeloma. Clin Exp Med. 2007;7:83-97.
17. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma: results of a North American phase III study (MM-009). Proc Am Soc Clin Oncol. 2006;24:Abstract 7521.
18. Dimopoulos MA, Spencer A, Attal M, et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma: results of a phase 3 study (MM-010). Blood. 2005; 106:Abstract 6.
19. Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007;47:1466-75.
20. Lederman L. International Myeloma Foundation. ASCO 2007 Highlights for Physicians. Available at: http://myeloma.org/ main.jsp?source=link&source_link_id=2803&type= article&tab_id=8&menu_id=0&id=2183. Accessed March 7, 2008.
21. Kastritis E, Mitsiades CS, Dimopoulos MA, Richardson PG. Management of relapsed and relapsed refractory myeloma. Hematol Oncol Clin North Am. 2007;21:1175-215.
22. Chanan-Khan AA, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109:2604-6.
23. Jagannath S, et al; SUMMIT/CREST Investigators. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer. 2005;103:1195-200.
24. United States Food and Drug Administration Bortezomib Prescribing Information. Available at www.fda.gov/cder/foi/label/2008/021602sO15lbl. pdf. Accessed July 21, 2008.
25. Lonial S, Waller EK, Richardson P, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106:3777-84.
26. Manochakian R, Miller KC, Chanan-Khan AA. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. Oncologist. 2007;12:978-90.
27. Chauhan D, Singh A, Velankar M, et al. Distince dynamic profiles for NPI-0052- and bortezomib-induced apoptosis in multiple myeloma. Blood. 2006;108:970a. Abstract 3396.
28. Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin. 2007;57:301-18.
29. Chauhan D, Singh A, Brahmandam M, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2008;111:1654-64.
30. Anderson KC. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol. 2007; 35:155-62.
31. Harousseau JL. Role of stem cell transplantation. Hematol Oncol Clin North Am. 2007;21:1157-74.
32. United States Food and Drug Administration. Bortezomib: supplemental new drug application approval letter (NDA 21-602/S-015). June 20, 2008. Available at www.fda.gov/cder/foi/appletter/2008/021602se1-015ltr.pdf. Accessed June 24, 2008.
33. Facon T, Darre S. Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation. Best Pract Res Clin Haematol. 2007;20:737-46.
34. Dispenzieri A. Complications of myeloma therapy. Hematol Oncol Clin North Am. 2007;21:1247-73.
35. Joshua D. Pathophysiology - bone disease. Presented at: XIth International Myeloma Workshop; June 5-30, 2007; Kos, Greece. Available at: http://myeloma.org/main.jsp?source=link&source_link- id=3039&type=article&tab_id=13&menu_id=0&id=2305. Accessed March 14, 2008.
36. Garrett IR, Chen D, Gutierrez G, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest. 2003;111:1771-82.
37. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced myeloma. N Engl J Med. 1996;334:488-93.
38. Multiple Myeloma Research Foundation. Bisphosphonate overview. Available at: www.multiplemyeloma.org/treatments/3.06.php. Accessed March 16, 2008.
39. Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005;136:1658-68.
40. Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clan Proc. 2006;81:1047-53.
41. Barosi G, Boccadoro M, Cavo M, et al. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:717-41.
42. Burris HA. Agents in development for multiple myeloma. Managed Care Oncol. Spring 2007;3:22-23, 59.
43. Siegel D, Mazumder A, Borrello I, et al. Update on phase I clinical trial of IPI-504, a novel, water-soluble Hsp90 inhibitor, in patients with relapsed/ refractory multiple myeloma. Blood. 2006;108:Abstract 3579.